Short-term effects of empagliflozin on preventing contrast induced acute kidney injury in patients undergoing percutaneous coronary intervention, a randomised trial by Zeinab Sadat Hosseini, Mohammad Javad Jamili, Behzad Ensan, Ghazaleh Donyadideh, Bahram Shahri, Hamid Eshraghi, Susan Darroudi, Mohsen Moohebati

Subjects: Get full text

Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near by Gilda M. Portalatin, Irene Hong-McAtee, Irene Hong-McAtee, Anna M. Burgner, Edward R. Gould, Tracy E. Hunley, Tracy E. Hunley

Subjects: “…empagliflozin…”
Get full text

Metabolic and functional factors associated with a change in resting metabolic rate among older adults with type 2 diabetes– results from the CEV-65 randomized trial by Assaf Buch, Roy Eldor, Ofer Kis, Arie Ben-Yehuda, Gizell Green, Yona Greenman, Sharon Barak

Subjects: Get full text

Empagliflozin Alleviates Hepatic Steatosis by Activating the AMPK-TET2-Autophagy Pathway in vivo and in vitro by Ting Li, Ting Fang, Linxin Xu, Xiangyang Liu, Xiaoyu Li, Mei Xue, Xiaochen Yu, Bei Sun, Liming Chen

Subjects: “…empagliflozin…”
Get full text

Corrigendum: Empagliflozin alleviates hepatic steatosis by activating the AMPK-TET2-autophagy pathway in vivo and in vitro by Ting Li, Ting Fang, Linxin Xu, Xiangyang Liu, Xiaoyu Li, Mei Xue, Xiaochen Yu, Bei Sun, Liming Chen

Subjects: “…empagliflozin…”
Get full text

Adjuvant Treatment with Empagliflozin or Semaglutide Increases Endothelial Progenitor Cells in Subjects with Well-Controlled Type 1 Diabetes Mellitus by Maja Preložnik Navodnik, Katarina Reberšek, Katarina Klinar, Andrej Janež, Helena Podgornik

Subjects: Get full text